Clinical Trial Update: GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating GP2013, a rituximab biosimilar, in Japanese patients with CD20-positive low-tumor-burden indolent B-cell non-Hodgkin lymphoma has been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent B-cell Non-hodgkin Lymphoma

Drugs mentioned

• GP2013 (rituximab biosimilar)

Snippet

Sponsor: Sandoz | Conditions: Indolent B-cell Non-Hodgkin's Lymphoma | Phase 1 | Status: COMPLETED